The FDA has approved the following drugs in April and May:
- Taclonex Scalp Suspension (calcipotriene; betamethasone diproprionate) details
- A variety of cetirizine products from various vendors continues to enter the marketplace.
- Patanase nasal spray (olapatadine) detail
- Treximet (sumatriptan/naproxen sodium) detail
- Aplenzin (buproprion hydrobromide) detail
0 Responses to “April/May NDAs”